ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

aflibercept

Also written as “Aflibercept”, “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” and “aflibercept injection (VEGF Trap-Eye, BAY86-5321)”.

Its studies are mostly in Macular Degeneration · Macular Edema · Colorectal Neoplasms · Lymphoma, Non-Hodgkin · Retinal Vein Occlusion, led by 15 companies.

Drug pageAflibercept: every studyMany companies study it; this page follows only the 86 they lead. All 268 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 2, 201286 company-led studies, 5 open or runningNext primary completion: Jul 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticalsits history only251 open or runningphase 4since Nov 2, 2012May 13, 2002none ahead
Bayer230 open or runningphase 4since Apr 10, 2014Mar 12, 2008none ahead
Sanofiits history only200 open or runningphase 3since May 16, 2006Jan 30, 2006none ahead
Novartisits history only40 open or runningphase 4since Jul 22, 2016Jul 22, 2016none ahead
Amgenits history only31 open or runningphase 3since Feb 13, 2020Feb 13, 2020Jul 31, 2027phase 3 · NCT07614776
Sam Chun Dang Pharm.its history only20 open or runningphase 3since Jul 17, 2020Jul 17, 2020none ahead
AbbVieits history only11 open or runningphase 2since Mar 16, 2022Mar 16, 2022Jun 2031phase 2 · NCT05296447
AO GENERIUMits history only11 open or runningphase 3since Sep 18, 2026Sep 18, 2026May 2028phase 3 · NCT07844148
bioeq-gmbhits history only10 open or runningphase 3since Aug 11, 2020Aug 11, 2020none ahead
cinnagenits history only10 open or runningphase 3since Sep 18, 2022Sep 18, 2022none ahead

Also a collaborator on its studies: REGENXBIO and Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bayer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 7 studies since Mar 12, 2008.

  1. Apr 10, 2014Phase 4 study in Neovascular Macular DegenerationNCT02120950 · 333 enrolled · Australia, Germany, Hong Kong and more
  2. Nov 28, 2014Phase 4 study in Wet Macular DegenerationNCT02305238 · 288 enrolled · Japan
  3. Mar 18, 2015Phase 3 study in Glaucoma, NeovascularNCT02396316 · 54 enrolled · Japan
  4. Sep 2, 2015Phase 3 study in Macular DegenerationNCT02540954 · 336 enrolled · Austria, Canada, Czechia and more
  5. Oct 20, 20152 phase 4 studiesNCT02581995, NCT02581891
  6. Jun 10, 2016Phase 4 study in Retinal Vein OcclusionNCT02800642 · 162 enrolled · Australia, Canada, Denmark and more
  7. Jun 28, 2016Phase 3 study in Macular EdemaNCT02818998 · 463 enrolled · Austria, Canada, Czechia and more
  8. Aug 17, 2018Phase 3 study in Glaucoma, NeovascularNCT03639675 · 16 enrolled · Japan
  9. Jun 28, 20192 phase 3 studies in Retinopathy of PrematurityNCT04015180, NCT04004208
  10. Jul 21, 2022Named afliberceptINNProposed as its International Nonproprietary Name in WHO's List 127
  11. Jul 22, 2022Phase 4 study in Macular DegenerationNCT05473715 · 3 enrolled · Canada, United Kingdom
  12. Aug 19, 2022Phase 4 study in Diabetic Macular EdemaNCT05511038 · 100 enrolled · India
  13. Apr 28, 2023Phase 3 study in Macular Edema Secondary to Retinal Vein OcclusionNCT05850520 · 892 enrolled · United States, Australia, Austria and more
  14. May 15, 2024Phase 3 study in Diabetic Macular EdemaNCT06422507 · 333 enrolled · China, Hong Kong
  15. Sep 8, 2024Phase 4 study in Diabetic Macular EdemaNCT06591598 · 51 enrolled · Czechia, Hungary, Slovakia

TargetBeta

PGF →VEGFA →read by rule
“Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor”ChEMBL 37, by rule

Studies

All 23 Bayer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06591598Diabetic Macular Edema · Czechia, Hungary, Slovakia4CompletedOct 14, 202551
NCT06422507Diabetic Macular Edema · China, Hong Kong3CompletedDec 29, 2025333
NCT05850520Macular Edema Secondary to Retinal Vein Occlusion · United States, Australia, Austria and more3CompletedNov 7, 2024892
NCT05511038Diabetic Macular Edema · India4CompletedApr 16, 2024100
NCT05473715Macular Degeneration · Canada, United Kingdom4TerminatedJul 11, 20233
NCT04015180Retinopathy of Prematurity · Argentina, Belgium, Brazil and more3CompletedSep 19, 2025100
NCT04004208Retinopathy of Prematurity · Argentina, Austria, Belgium and more3CompletedFeb 12, 2021113
NCT03639675Glaucoma, Neovascular · Japan3CompletedFeb 14, 201916
NCT02818998Macular Edema · Austria, Canada, Czechia and more3CompletedNov 13, 2018463
NCT02800642Retinal Vein Occlusion · Australia, Canada, Denmark and more4CompletedJul 31, 2019162
NCT02581995Macular Edema · Austria, Canada, Czechia and more4CompletedAug 9, 2017560
NCT02581891Macular Degeneration · Australia, Canada, France and more4CompletedApr 26, 2019287
NCT02540954Macular Degeneration · Austria, Canada, Czechia and more3CompletedDec 24, 2019336
NCT02396316Glaucoma, Neovascular · Japan3CompletedJun 16, 201654
NCT02305238Wet Macular Degeneration · Japan4CompletedDec 22, 2016288
NCT02120950Neovascular Macular Degeneration · Australia, Germany, Hong Kong and more4CompletedAug 12, 2016333
NCT01783886Macular Edema · China, Hong Kong, Korea, Republic of and more3CompletedMar 2015381
NCT01512966Macular Edema · Japan3CompletedSep 201373
NCT01482910Macular Degeneration · China3CompletedMar 2014304
NCT01331681Diabetes Mellitus · Australia, Austria, Czechia and more3CompletedJun 3, 2013406
NCT01249664Myopia, Degenerative · Hong Kong, Japan, Korea, Republic of and more3CompletedFeb 2013122
NCT01012973Retinal Vein Occlusion · Australia, Austria, France and more3CompletedFeb 2011177
NCT00637377Macular Degeneration · Argentina, Australia, Austria and more3CompletedSep 20101,240

How it is read

Names in the registry

  • “Aflibercept”, 9 entries
  • “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)”, 8 entries
  • “aflibercept injection (VEGF Trap-Eye, BAY86-5321)”, 8 entries
  • “aflibercept”, 7 entries
  • “Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)”, 7 entries

Codes read as this program: BAY865321, SCD411.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.